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Objectives The aim of this study was to assess risk prediction by different biomarkers in patients with an ongoing non–ST-
segment elevation acute coronary syndrome (NSTE-ACS) and after clinical stabilization.
Background Different biomarkers reflect different aspects of the pathobiology in NSTE-ACS. However, there is little informa-
tion regarding their relative prognostic value during the time course of disease.
Methods The N-terminal pro-brain natriuretic peptide (NT-proBNP), C-reactive protein (CRP), cardiac troponin I (cTnI), and the
estimated glomerular filtration rate (eGFR) were measured at randomization and after 6 weeks and 6 months in 877
NSTE-ACS patients included in the FRISC (FRagmin and fast revascularization during InStability in Coronary artery dis-
ease) II trial. The biomarkers’ prognostic value during 5-year follow-up was evaluated by Cox regression models, calcu-
lation of the c-statistics, and estimation of the net reclassification improvement (NRI).
Results Among the biomarkers measured at randomization, NT-proBNP was the strongest predictor for mortality (ad-
justed hazard ratio [HR]: 1.7; 95% confidence interval [CI]: 1.3 to 2.1; p  0.001). Even during follow-up, NT-
proBNP demonstrated the strongest association to the composite end point of death/myocardial infarction (ad-
justed HR at 6 weeks: 1.5; 95% CI: 1.3 to 1.7; p  0.001; adjusted HR at 6 months: 1.4; 95% CI: 1.2 to 1.7; p 
0.001). Even CRP was independently predictive at 6 months for the composite end point (adjusted HR: 1.3; 95%
CI: 1.1 to 1.5; p  0.003). Only 6-week results of NT-proBNP provided significant incremental prognostic value to
established risk indicators regarding the composite end point (c-statistics 0.69 [p  0.03]; NRI 0.11 [p  0.03]).
Conclusions The NT-proBNP is an independent risk predictor in patients with ongoing NSTE-ACS and after clinical stabilization. The
CRP exhibits increasing predictive value at later measurements. However, only NT-proBNP provided incremental prog-
nostic value and might therefore be considered as a complement for early follow-up controls after NSTE-ACS. (J Am
Coll Cardiol 2009;54:357–64) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.056t
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Piochemical markers play a major role for risk assessment in
atients with an ongoing non–ST-segment elevation acute
oronary syndrome (NSTE-ACS). In particular the cardiac
roponins are generally recognized as important risk indica-
ors but also markers of left ventricular performance (i.e.,
-terminal pro-brain natriuretic peptide [NT-proBNP]),
nflammation (i.e., C-reactive protein [CRP]), and renal
unction (i.e., estimated glomerular filtration rate [eGFR])
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009, accepted March 10, 2009.hat provide strong prognostic information (1,2). Emerging
vidence furthermore suggests that these biomarkers are
rognostically useful even in the late phase after a NSTE-
CS (3–8), with the natriuretic peptides having been most
xtensively evaluated (3,4). However, the evolution of the
rognostic implications of different biomarkers during and
fter an NSTE-ACS has not been assessed so far.
See page 365
The purpose of this study was thus to investigate the
rognostic value of cardiac troponin I (cTnI), NT-proBNP,
RP, and the eGFR relative to each other and in the
ontext of other established risk indicators in patients with
n ongoing NSTE-ACS and at 6 weeks and 6 months after
linical stabilization.
ethods
atients and study design. The protocol and main results
f the FRISC (FRagmin and fast revascularization during
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disease) II trial have been pub-
lished elsewhere (9,10). This trial
was a prospective, multicenter
study randomizing 3,489 pa-
tients with NSTE-ACS between
1996 and 1998 in a factorial de-
sign to an early invasive or non-
invasive strategy and to 3-month
treatment with dalteparin or pla-
cebo. Patients were included in
case of symptoms of unstable
coronary artery disease with ob-
jective signs of myocardial isch-
emia, such as electrocardio-
graphic changes (ST-segment
depression 0.1 mV or T-wave
nversion 0.1 mV) or elevated biochemical markers of
yocardial necrosis. Major exclusion criteria were increased
isk of bleeding, serum creatinine 150 mol/l, percutane-
us coronary intervention during the last 6 months, and a
ecision to perform coronary angiography or percutaneous
oronary intervention before randomization. Patients with a
istory of previous open heart surgery, advanced age, or
oor general health and those included after completion of
ecruitment to the invasive versus noninvasive arm were
reated primarily noninvasively and randomized only re-
arding prolonged treatment with dalteparin or placebo. In
he invasive strategy, the aim was to perform coronary
ngiography and, if appropriate, revascularization within 7
ays from admission. Patients randomized to the noninva-
ive strategy underwent coronary angiography only in case
f refractory or recurrent angina or if they showed signs of
evere ischemia on a pre-discharge exercise test. Informed
onsent was obtained from all patients, and the protocol was
pproved by all local ethics committees.
Patients were followed after randomization by outpatient
isits after 6 (range 4 to 7) weeks and 3 and 6 months. At
hese instances, a blood sampling program was performed at
elected study centers including 1,380 patients. Further
ollow-up was performed by telephone contacts after 12 and
4 months. Thereafter and up to 5 years after randomiza-
ion, all information on events was based on mandatory
ational Registries run by the Swedish Health Authority.
aboratory analysis. The cTnI, NT-proBNP, and CRP
ere determined in frozen (70°C), not previously thawed,
amples of ethylenediaminetetraacetic acid-plasma obtained
t randomization and follow-up at 6 weeks and 6 months.
or follow-up measurements, only results from patients
ithout an acute myocardial infarction (AMI) or a coronary
evascularization procedure during the previous 14 days
ere considered. The cTnI was measured with the Access
ccuTnI assay (Beckman Coulter, Inc., Fullerton, Califor-
ia). For randomization samples, the original version of this
ssay was used, and results were dichotomized at its 99th
ercentile of 0.04 g/l (11). Samples obtained during
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CRP  C-reactive protein
cTnI  cardiac troponin I
eGFR  estimated
glomerular filtration rate
NRI  net reclassification
improvement
NSTE-ACS  non–ST-
segment elevation acute
coronary syndrome
NT-proBNP  N-terminal
pro-brain natriuretic peptideollow-up were analyzed with the refined assay version, thich is characterized by an improved analytical perfor-
ance at low cTnI concentrations with 0.014 g/l as the
owest concentration measurable with a coefficient of vari-
tion 10% and 0.006 g/l as the lower level of detection
5). Following previous experiences, follow-up cTnI results
ere dichotomized at 0.01 g/l (5).
The NT-proBNP was measured at all instances with the
lecsys proBNP sandwich immunoassay on an Elecsys 2010
nstrument (Roche Diagnostics, Mannheim, Germany).
he CRP was analyzed with the Immulite CRP assay
Diagnostic Products Corp., Los Angeles, California). Se-
um creatinine was determined locally, and the eGFR was
alculated according to the 4-variable version of the Mod-
fication of Diet in Renal Disease formula (12).
tatistical analysis. The study end points for the present
nalysis were total mortality and AMI, alone or as compos-
te, after each respective measurement instance. For patients
ith an AMI during the first 6 months of follow-up, the
ime to the next AMI or end of follow-up was calculated.
The prognostic value of the tested biomarkers was inves-
igated by different Cox proportional hazard models. Ad-
ustment was made for age, sex, diabetes, a history of heart
ailure and a history of AMI (model 1). Covariates were
efined as follows:
Diabetes: history of diabetes (randomization results)
and/or antidiabetic treatment and/or a pre-test fasting
glucose 6.1 mmol/l (follow-up results).
Heart failure: history of heart failure (randomization
results) and/or left-ventricular ejection fraction0.45
during the index hospital stay (follow-up results).
Previous AMI: history of AMI (randomization results)
and/or AMI as index event (defined as cardiac tropo-
nin T 0.035 g/l at randomization [11]) and/or
recurrent AMI during follow-up and before the re-
spective measurement instance (follow-up results).
Additional adjustment was made for the 4 tested biomar-
ers (model 2) and for coronary revascularization before the
espective measurement instance during follow-up (model
). We decided to focus on coronary revascularization
nstead for the randomized treatment strategy with regard to
ome crossover between the randomization arms during
ollow-up. The proportional hazard assumptions were
hecked by computing log[log(event)] plots. The func-
ional form of the association between outcome and each
espective biomarker was assessed by the inspection of
eneralized additive model plots, which revealed nonlinear
ssociations between the eGFR (all measurements) and
RP (at randomization). Therefore we dichotomized the
GFR at 75 ml/min/1.73 m2 (13) and excluded random-
zation CRP results from all multivariable analyses, because
he nonlinear association could not be compensated by
athematical transformations. The cTnI was dichotomized
n the basis of the respective cutoffs, whereas NT-proBNP
nd CRP (at 6 weeks and 6 months) were entered as ln
ransformed variables.
e
a
c
c
A
u
S
r
t
P
i
c
T
e
1
a
W
q
v
a
s
I
N
R
C
b
a
t
s
4
t
(
t
n
r
p
p
359JACC Vol. 54, No. 4, 2009 Eggers et al.
July 21, 2009:357–64 Risk Prediction During and After NSTE-ACSThe incremental prognostic value of the tested biomark-
rs during follow-up to the covariates applied in model 1
nd regarding the composite end point was tested first, by
alculating the respective c-statistics. The differences in
-statistics were estimated with the method described by
ntolini et al. (14). The Hosmer-Lemeshow statistic was
sed to assess the goodness of fit of the applied models.
econd, the increased discriminative value of the biomarkers
egarding the composite end point was studied by assessing
he net reclassification improvement (NRI) as described by
encina et al. (15). This method determines the difference
n the probabilities of a subject to belong to predefined risk
ategories before and after the addition of a specific marker.
wo models were used for prognostic classification based on
stimated risk tertiles and estimated risks of 10%, 10% to
9.9%, and 20%, respectively.
Continuous variables are described as medians with 25th
nd 75th percentiles and were compared with the Mann-
hitney U test. Categoric variables are expressed as fre-
uencies and percentages. Differences between categoric
ariables were analyzed with the chi-square test. In all tests,
Figure 1 Patient Flow Chart
Patient cohorts and occurrence of adverse events. AMI  acute myocardial infarct
PCI  percutaneous coronary intervention; FRISC  FRagmin and fast revascularizp value 0.05 was considered significant. The statistical
oftware packages SPSS version 14.0 (SPSS Inc., Chicago,
llinois) and SAS version 9.1 (SAS Institute Inc., Cary,
orth Carolina) were used.
esults
linical characteristics. Randomization results for all 4
iomarkers were available in 877 subjects. The sample sizes
t 6 weeks and 6 months are given in Figure 1.
The clinical characteristics of the sample population and
he results of the tested biomarkers at the different mea-
urement instances are demonstrated in Table 1. In total,
42 patients (50%) had been randomized to 3-month
reatment with dalteparin. Three hundred sixty-five patients
42%) had been randomized to the invasive strategy, 365 to
he noninvasive strategy (42%), and 147 patients (16%) had
ot been randomized regarding these strategies. Coronary
evascularization had been performed at 6 weeks in 455
atients (52%) of the entire sample population and in 514
atients (60%) at 6 months.
BG  coronary artery bypass grafting;
uring InStability in Coronary artery disease trial.ion; CA
ation d
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Risk Prediction During and After NSTE-ACS July 21, 2009:357–64rognostic evaluation. During 5-year follow-up, 79 pa-
ients (9.0%) died, 152 patients (17%) had at least 1 recurrent
MI, and 198 patients (23%) suffered the composite end
oint. The occurrence of events is illustrated in Figure 1.
At randomization, NT-proBNP was the strongest pre-
ictor for mortality and cTnI0.04 g/l for both AMI and
he composite end point (Table 2). The eGFR at random-
zation did not provide independent prognostic informa-
ion. When added as a ln transformed continuous variable,
RP neither altered the hazard ratios for the other tested
arkers considerably nor emerged as an independent pre-
ictor of events (data not shown).
Even during follow-up, NT-proBNP was the strongest
redictor for mortality and AMI. The CRP was also
redictive for death and AMI, in particular at 6 months.
he cTnI and the eGFR provided only limited prognostic
alue and before final adjustment. These associations re-
ained unchanged when follow-up cTnI results were en-
ered into the multivariable analysis as ln transformed
ariables (data not shown).
When the tested biomarkers were added to prognostic
odels based on conventional risk indicators, only NT-
roBNP at 6 weeks provided incremental value associated
ith a significant increase of the c-statistics from 0.66 to
Clinical Characteristics of the Study Populationat Randomiz tion and After 6 Weeks and 6 MonTable 1 Cl nic l Charact ris ics of the Studat Randomization and After 6 Week
Randomizatio
(n  877)
Age (yrs) 66.9 (59.3–73
Male 625 (71.3)
Previous smoking 321 (36.6)
Current smoking 200 (22.8)
Hypertension 288 (32.8)
Heart failure 35 (4.0)
Diabetes 112 (12.8)
Previous stroke 42 (4.8)
Previous AMI 242 (27.6)
Previous PCI/CABG 91 (10.4)
Treatment
Acetylsalicylic acid 391 (44.6)
Beta-blockers 336 (38.3)
ACE inhibitors 120 (13.7)
Calcium antagonists 160 (18.2)
Digitalis 24 (2.7)
Diuretics 150 (17.1)
Long-acting nitrates 207 (23.6)
Lipid-lowering drugs 113 (12.9)
Biomarker results
cTnI 0.04 g/l 391 (44.6)
cTnI 0.01 g/l —
NT-proBNP (ng/ml) 518 (201–124
CRP (mg/l) 5.9 (2.9–13.4
eGFR 75 ml/min/1.73 m2 435 (49.6)
Values are shown as n (%) and median (25th to 75th percentiles). Smo
had not been systematically assessed during follow-up.
ACE angiotensin-converting enzyme; AMI acute myocardial infar
 cardiac troponin I; eGFR  estimated glomerular filtration rate; N
coronary intervention..69 (p  0.03). Even at 6 months, addition of NT- mroBNP resulted in the greatest increase of the c-statistics
ut without reaching statistical significance (Table 3). The
T-proBNP at 6 weeks was also the only marker to provide
significant NRI (Figs. 2A and 2B). This was due to a
ubstantial proportion of patients being downgraded regard-
ng their risk category after addition of NT-proBNP to the
isk models (19% of all patients in both models).
iscussion
he prognostic importance of biomarkers reflecting differ-
nt pathophysiologic entities related to risk is well estab-
ished in the acute phase of NSTE-ACS. However, the
vidence regarding the evolution of the prognostic informa-
ion provided by biomarkers at later stages of the disease is
till somewhat limited. Our results extend previous data
rom the FRISC II study (3,16), demonstrating that NT-
roBNP is a strong predictor of adverse events in NSTE-
CS, both throughout the entire 6-month sampling period
nd even in the context of other clinical risk indicators,
ncluding biomarkers of cardiomyocyte necrosis, inflamma-
ion, and renal dysfunction. The NT-proBNP levels were
articularly predictive for mortality, probably because they
eflect larger infarct size, progressive remodeling, and thus a
ulation
6 Months
6 Weeks
(n  869)
6 Months
(n  856)
67.1 (59.6–73.8) 67.3 (59.8–74.0)
617 (71.0) 607 (70.9)
— —
— —
— —
137 (15.8) 128 (15.0)
159 (18.3) 153 (17.9)
— —
716 (82.4) 706 (82.5)
455 (52.4) 514 (60.0)
— 817 (95.6)
— 707 (82.7)
— 158 (18.5)
— 169 (19.7)
— 27 (3.2)
— 162 (18.9)
— 259 (30.3)
— 460 (53.7)
— —
414 (47.6) 301 (35.2)
346 (153–776) 232 (113–503)
2.5 (1.4–5.1) 2.3 (1.2–4.4)
488 (56.2) 484 (56.5)
tus, the prevalence of hypertension and new strokes, and medication
ABG coronary artery bypass grafting; CRP C-reactive protein; cTnI
NP  N-terminal pro-brain natriuretic peptide; PCI  percutaneousthsy Pop
s and
n
.6)
2)
)
king sta
ction; Core pronounced degree of myocardial dysfunction (17,18).
PM
(
r
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July 21, 2009:357–64 Risk Prediction During and After NSTE-ACSrognostic Value of Biochemical Markers Measured at Different Time PointsTable 2 Prognostic Value of Biochemical Markers Measured at Different Time Points
Randomization
Model 1 (n  877) Model 2 (n  877)
HR (95% CI) p Value HR (95% CI) p Value
Death
cTnI 0.04 g/l 1.8 (1.0–3.3) 0.05 0.9 (0.5–1.8) 0.82
NT-proBNP (ln) 1.7 (1.3–2.0) 0.001 1.7 (1.3–2.1) 0.001
eGFR 75 ml/min/1.73 m2 1.0 (0.6–1.5) 0.83 0.9 (0.6–1.4) 0.58
AMI
cTnI 0.04 g/l 2.5 (1.5–3.9) 0.001 2.5 (1.5–4.2) 0.001
NT-proBNP (ln) 1.2 (1.0–1.3) 0.05 1.0 (0.8–1.2) 0.76
eGFR 75 ml/min/1.73 m2 1.7 (1.2–2.4) 0.004 1.6 (1.2–2.3) 0.007
Death or AMI
cTnI 0.04 g/l 2.2 (1.5–3.2) 0.001 1.9 (1.2–3.0) 0.003
NT-proBNP (ln) 1.2 (1.1–1.4) 0.002 1.1 (0.9–1.2) 0.31
eGFR 75 ml/min/1.73 m2 1.3 (1.0–1.8) 0.05 1.3 (1.0–1.7) 0.10
6 Weeks
Model 1 (n  869) Model 2 (n  869) Model 3 (n  869)
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Death
cTnI 0.01 g/l 1.7 (1.1–2.8) 0.03 1.2 (0.7–1.9) 0.60 1.3 (0.8–2.2) 0.38
NT-proBNP (ln) 1.8 (1.5–2.2) 0.001 1.7 (1.4–2.2) 0.001 1.7 (1.3–2.2) 0.001
CRP (ln) 1.4 (1.1–1.7) 0.003 1.2 (1.0–1.5) 0.04 1.3 (1.0–1.5) 0.02
eGFR 75 ml/min/1.73 m2 1.0 (0.6–1.6) 0.98 0.9 (0.6–1.5) 0.68 0.9 (0.5–1.4) 0.60
Revascularization — — — — 0.6 (0.4–0.9) 0.02
AMI
cTnI 0.01 g/l 0.9 (0.6–1.4) 0.65 0.7 (0.5–1.0) 0.08 0.8 (0.6–1.2) 0.33
NT-proBNP (ln) 1.4 (1.2–1.7) 0.001 1.4 (1.2–1.8) 0.001 1.5 (1.2–1.7) 0.001
CRP (ln) 1.2 (1.0–1.4) 0.07 1.1 (0.9–1.3) 0.20 1.2 (1.0–1.4) 0.02
eGFR 75 ml/min/1.73 m2 1.6 (1.1–2.5) 0.02 1.5 (1.0–2.4) 0.05 1.2 (0.8–1.7) 0.34
Revascularization — — — — 0.6 (0.4–0.8) 0.003
Death or AMI
cTnI 0.01 g/l 1.1 (0.8–1.5) 0.73 0.8 (0.5–1.1) 0.15 0.8 (0.6–1.2) 0.33
NT-proBNP (ln) 1.5 (1.3–1.7) 0.001 1.5 (1.3–1.8) 0.001 1.5 (1.2–1.7) 0.001
CRP (ln) 1.2 (1.1–1.4) 0.004 1.2 (1.0–1.4) 0.04 1.2 (1.0–1.4) 0.02
eGFR 75 ml/min/1.73 m2 1.3 (0.9–1.8) 0.15 1.2 (0.8–1.7) 0.34 1.1 (1.0–1.2) 0.19
Revascularization — — — — 0.6 (0.4–0.8) 0.003
6 Months
Model 1 (n  856) Model 2 (n  856) Model 3 (n  856)
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Death
cTnI 0.01 g/l 2.4 (1.4–4.0) 0.001 1.6 (0.9–2.8) 0.13 1.6 (0.9–2.9) 0.10
NT-proBNP (ln) 2.1 (1.6–2.7) 0.001 1.8 (1.3–2.3) 0.001 1.8 (1.3–2.3) 0.001
CRP (ln) 1.5 (1.2–1.9) 0.001 1.3 (1.1–1.6) 0.02 1.3 (1.1–1.6) 0.02
eGFR 75 ml/min/1.73 m2 0.9 (0.5–1.6) 0.73 0.8 (0.5–1.4) 0.49 0.9 (0.5–1.5) 0.54
Revascularization — — — — 0.7 (0.4–1.1) 0.11
AMI
cTnI 0.01 g/l 1.5 (1.0–2.4) 0.07 1.3 (0.8–2.0) 0.37 1.3 (0.8–2.1) 0.28
NT-proBNP (ln) 1.4 (1.1–1.8) 0.006 1.3 (1.0–1.6) 0.06 1.3 (1.0–1.6) 0.06
CRP (ln) 1.3 (1.1–1.6) 0.006 1.3 (1.0–1.5) 0.02 1.3 (1.0–1.5) 0.02
eGFR 75 ml/min/1.73 m2 1.0 (0.6–1.5) 0.83 0.9 (0.6–1.5) 0.76 0.9 (0.6–1.5) 0.80
Revascularization — — — — 0.6 (0.4–1.0) 0.05
Death or AMI
cTnI 0.01 g/l 1.6 (1.1–2.4) 0.009 1.2 (0.8–1.8) 0.32 1.3 (0.9–1.9) 0.22
NT-proBNP (ln) 1.6 (1.3–1.9) 0.001 1.4 (1.2–1.8) 0.001 1.4 (1.2–1.7) 0.001
CRP (ln) 1.4 (1.2–1.6) 0.001 1.3 (1.1–1.5) 0.003 1.3 (1.1–1.5) 0.003
eGFR 75 ml/min/1.73 m2 1.0 (0.6–1.4) 0.77 0.9 (0.6–1.3) 0.61 0.9 (0.6–1.4) 0.69
Revascularization — — — — 0.7 (0.5–0.9) 0.02
odel 1: adjusted for age, sex, diabetes, heart failure, and previous AMI. Model 2: adjusted for the same variables as in Model 1 with the addition of cTnI0.04 g/l (randomization results) or0.01 g/l
6 weeks and 6 months results), ln NT-proBNP, ln CRP (6 weeks and 6 months), and eGFR 75 ml/min/1.73 m2. Model 3: adjusted for the same variables as in Model 2 with the addition of coronary
evascularization after randomization and before the respective measurement instance.
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.
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Risk Prediction During and After NSTE-ACS July 21, 2009:357–64owever, even myocardial ischemia augments the synthesis
f the natriuretic peptides (19), which might explain the
ssociation between NT-proBNP upon early follow-up and
ecurrent ischemic events.
Among the biomarkers measured at randomization, cTnI
as the strongest predictor for recurrent AMI but exhibited
o independent association with mortality. This finding
robably depends on the choice of the 99th percentile as a
rognostic cutoff. This cutoff has been shown to reflect an
ncreased likelihood of an unstable plaque with downstream
icroembolization of thrombotic material, which translates
nto a higher risk of recurrent ischemic events (20,21). The
isk for mortality, in contrast, is known to increase at higher
roponin peak levels, given the relation of troponin leakage
o the amount of infarcted myocardium (18,22).
Contrasting with the acute situation, cTnI elevation at a
hreshold below the 99th percentile was not related to
ecurrent AMI but predicted mortality. This indicates that
his lower cutoff might be more sensitive to detect left
entricular dysfunction after NSTE-ACS (23). However,
TnI was no longer prognostic after adjustment for other
iomarkers, including NT-proBNP, probably because the
atriuretic peptides more appropriately reflect impaired
ardiac performance (18). This does not exclude the possi-
ility that cTnI might exhibit stronger associations with risk
t even later time points, given its independent relation to
ortality in a recently assessed elderly community popula-
ion (24).
Even CRP emerged as an independent predictor when
easured during follow-up and became, despite decreasing
evels, more prognostic over time. Late after NSTE-ACS,
RP levels might reflect an increased myocardial cytokine
ctivation leading to remodeling, paving the way for heart
ailure and thereby to poor outcome (25). However, given
he prognostic value of CRP independent of NT-proBNP,
t is more probable that the prognostic implications of CRP
ate after NSTE-ACS are mediated by extramyocardial
-Statistics: Incremental Prognostic Value of Biochemical Markerseg rding the Co posite of Death or Myocardial Infarction DuringTable 3 C-Statistics: Incremental Prognostic Value of Bioch mRegarding the Composite of Death or Myocardial Infarc
C-Stati
6 weeks
Clinical risk indicators 0.66 (0.6
Clinical risk indicators  cTnI 0.01 g/l 0.67 (0.6
Clinical risk indicators  NT-proBNP (ln) 0.69 (0.6
Clinical risk indicators  CRP (ln) 0.67 (0.6
Clinical risk indicators  eGFR 75 ml/min/1.73 m2 0.67 (0.6
6 months
Clinical risk indicators 0.65 (0.6
Clinical risk indicators  cTnI 0.01 g/l 0.66 (0.6
Clinical risk indicators  NT-proBNP (ln) 0.68 (0.6
Clinical risk indicators  CRP (ln) 0.67 (0.6
Clinical risk indicators  eGFR 75 ml/min/1.73 m2 0.65 (0.6
linical risk indicators include age, sex, diabetes at the respective measurement instance, heart failur
Abbreviations as in Table 1.echanisms such as a chronic low-grade inflammation in phe coronary vasculature, as described in other stable pop-
lations (26).
We did not find, somewhat unexpectedly, associations
etween renal function and prognosis, which contrasts with
revious studies in patients with ongoing or recent NSTE-
CS (8,13). We assume that these findings are biased, due
o the exclusion of patients with renal failure in the FRISC
I study.
Our findings raise the question of whether and which
iochemical markers should be assessed in the stable phase
fter NSTE-ACS to improve prognostication. Current
ollow-up routines focus on symptomatic assessment and
odification of cardiovascular risk factors to halt the pro-
ression of atherosclerosis. However, these measures are in
art operator dependent, and conventional risk factors
ight not completely account for the individual risk profile,
hich also is known to change over time (27).
We found that measurement of NT-proBNP at 6 weeks
ight be particularly useful with regard to its incremental
alue to conventional risk indicators. Noteworthy, the as-
essment of NRI indicated that NT-proBNP levels allowed
or the reclassification of a relative large subset of patients
ithout events to lower categories of risk. Early measure-
ent of NT-proBNP might also be useful for the identifi-
ation of some high-risk subjects with persistent left ven-
ricular dysfunction after NSTE-ACS in whom optimization
harmacological treatment is mandatory. C-reactive pro-
ein, in contrast, provided no incremental prognostic infor-
ation in the tested models. However, with regard to its
ndependent association with events at 6 months and the
onsiderably improved calibration of our risk model at
his time point after addition of CRP, testing for this
iomarker could be useful for later follow-up controls
hen results would be integrated into more sophisticated
isk prediction tools than the exploratory model applied
n our analysis.
tudy limitations. This study is based on an NSTE-ACS
r Follow-Uparkers
During 5-Year Follow-Up
Calibration Hosmer-Lemeshow
p Value Chi-Square p Value
) 7.7 0.46
) 0.88 11.3 0.18
) 0.03 6.5 0.59
) 0.30 9.4 0.31
) 0.54 10.9 0.21
) 18.3 0.02
) 0.48 10.2 0.25
) 0.07 10.0 0.26
) 0.16 4.7 0.79
) 0.59 13.0 0.11
respective measurement instance, and previous AMI before the respective measurement instance.5-Yeaical M
tion
stics
3–0.72
2–0.71
5–0.73
3–0.72
2–0.71
0–0.70
1–0.71
3–0.73
2–0.72
0–0.70opulation randomized more than 10 years ago (i.e., before
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July 21, 2009:357–64 Risk Prediction During and After NSTE-ACShe current era of intense secondary prevention with aden-
sine diphosphate inhibition, angiotensin-converting en-
yme inhibitors, and high-dose statins) and therefore needs
o be validated in a contemporary sample. Furthermore, we
ssessed a pre-selected patient population, and the sample
ize was somewhat limited. Therefore we cannot exclude
he possibility that CRP and the eGFR might exhibit
tronger associations with risk when assessed in a larger
nd more unselected population. Due to a lack of
emaining samples, we could not perform re-analyses of
Figure 2 NRI Regarding the Composite of Death or Myocardial
Follow-Up After Addition of NT-proBNP Levels at 6 We
(A) Risk categories defined by estimated risk tertiles. (B) Risk categories defined
patients within the respective risk categories, considering those who had been do
weeks after the addition of ln N-terminal pro-brain natriuretic peptide (NT-proBNP)
cardial infarction). The solid parts of the bars depict the proportion of patients wh
ber of patients with an event is given at the top of each bar. NRI  net reclassificTnI at randomization with the refined version of the pccuTnI assay. Thus, cTnI results were obtained with 2
terations of this assay with different prognostic cutoffs,
hich limits the transferability of results obtained at
andomization to follow-up results. The focus on coro-
ary revascularization versus no revascularization might
ave weakened the relationships between the biomarkers
nd risk, because the decision to revascularize patients
rom other than the invasive arm was based on clinical
ecisions with a potential higher rate of sicker patients
ith higher biomarker levels being treated with this
ction During 5-Year
o Conventional Risk Indicators
imated risks of 10%, 10% to 19.9%, and 20%. Bars indicate numbers of
ed or upgraded and those who remained within the same risk category at 6
to conventional risk indicators (age, sex, diabetes, heart failure, previous myo-
the composite end point after 6 weeks and within 5 years of follow-up. The num-
improvement.Infar
eks t
by est
wngrad
levels
o met
ationrognostically beneficial therapy.
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Risk Prediction During and After NSTE-ACS July 21, 2009:357–64onclusions
ardiac troponin I, NT-proBNP, and CRP exhibit differ-
nt and changing relations to adverse events in patients with
STE-ACS, both in the acute phase and after clinical
tabilization. The NT-proBNP was independently predic-
ive for adverse outcome throughout the entire 6-month
bservation period and should be considered for improve-
ent of risk stratification during early follow-up. Even
easurement of CRP might be a useful tool for risk
tratification at a later time point (e.g., after 6 months). The
ventual incremental value of slight elevations of troponin
etermined with highly sensitive assays will need further
valuation in larger patient cohorts with stable coronary
rtery disease.
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